Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00209027 · ClinicalTrials.gov registry record · NA
The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia
A NA study, sponsored by Emory University.
- Terminated
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT00209027 is a NA study that was terminated before completion, run by Emory University. The registered enrollment target is 20 participants.
The verdict
NCT00209027, a NA study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
The objective of this study is to determine whether subjects with negative symptoms of schizophrenia have abnormal functioning of brain circuits relevant to reward processing, and to determine whether any such abnormalities are normalized by treatment with aripiprazole.
Interventions
- OTHER fMRI
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-04 |
| Est. Completion | 2011-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00209027
The ClinicalTrials.gov registry entry for NCT00209027 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which fMRI is the first listed.
NCT00209027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00209027 about?
NCT00209027 is a clinical study titled "The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia". The objective of this study is to determine whether subjects with negative symptoms of schizophrenia have abnormal functioning of brain circuits relevant to reward processing, and to determine whether any such abnormalities are normalized by treatment with aripiprazole.
What is the current status of trial NCT00209027?
This trial is currently terminated. It is a NA study. The enrollment target is 20 participants. The study started on 2005-04. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00209027?
The interventions under investigation include: fMRI (OTHER), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00209027?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.